Pilar De La Huerta
Member of the Supervisory Board
General Science
bti bioteach
Spain
Biography
Pilar de la Huerta has accumulated an extensive experience in the pharma and biotech sector over the last 20 years. She joined Genetrix group as a CEO in 2010, moving to SYGNIS after the merger done between Xpol, Genetrix subsidiary, and SYGNIS AG in october 2012. From 2006 to 2010, she was a strategic consultant within several companies, such as Viamed Salud Group, where she was responsible for R&D and New Business and was appointed CEO of the two most innovative companies within the Group: Araclon Biotech, SL. and Viamed Technology Investments. Before that, she was CEO at Neuropharma (Noscira, Zeltia Group) and assumed various responsibilities within the Zeltia Group, (the biggest quoted biotech holding in Spain). Pilar holds a Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University. She has been appointed as board member of several Spanish companies during the last 10 years, but have left most of them to dedicate her time 100% to the new SYGNIS. Currently, she is part of the management board of SYGNIS. CEO and Board Member of Antibióticos de Leon (ADL, S.A.)
Research Interest
General Science
